唐氏综合征母体血清蛋白表达特点及定量质谱测定价值分析

Value Analysis of Maternal Serum Protein Expression and Quantitative Mass Spectrometry in Down Syndrome

目的:筛选唐氏综合征母体血清蛋白标记物,分析唐氏综合征母体血清蛋白表达特点,研究定量质谱技术在唐氏综合征母体血清蛋白测定中的价值。方法:收集我院在2013年6月至2017年8月间接受唐氏综合征筛查孕中期女性,将胎儿确诊唐氏综合征的30例孕妇作为观察组,将30名健康孕妇作为对照组,应用同位素标记绝对和相对定量质谱技术测定(i TRAQ技术)鉴定血清蛋白及血清蛋白相对表达量,用ELISA法验证母体血清候选蛋白含量。结果:i TRAQ定量质谱技术得到高可信差异蛋白26个,包括上调蛋白18个,下调蛋白8个,PANTHER软件分析显示26个蛋白涉及介导蛋白质结合功能、抗氧化活性、催化功能、结构分子活性和转运功能共5种功能;与对照组比较,观察组血清CP和SOD明显升高,P<0.05差异有统计学意义。结论:定量质谱技术能鉴别多种唐氏综合征母体血清蛋白标记物差异,其中血清过氧化物歧化酶-1蛋白、血清铜蓝蛋白有望成为唐氏综合征筛查母体血清蛋白标记物。

Objective:To screen maternal serum protein markers in Down's syndrome.To analyze the expression characteristics of maternal serum proteins in Down's syndrome.Objective to study the value of quantitative mass spectrometry in the determination of serum proteins in Down syndrome patients.Methods:30 pregnant women who received Down's syndrome in the middle of the pregnancy from June 2013 to August 2017 were selected as the observation group.30 healthy pregnant women were used as the control group.Isotope labeled absolute and relative quantitative mass spectrometry(iTRAQ)was used to determine the relative expression of serum protein and serum protein.The ELISA method was used to verify the content of the candidate protein in the maternal serum.Results:There were 26 high credible proteins,including 18 upregulated proteins and 8 down regulated proteins,by iTRAQ quantitative mass spectrometry.The PANTHER software analysis showed that 26 proteins involved 5 functions,including protein binding,antioxidant activity,catalytic function,structure and molecular activity and transport function.Compared with the control group,the serum CP and SOD levels in the observation group were significantly higher than those in the control group,and the difference was statistically significant between P<0.05.Conclusion:Quantitative mass spectrometry can identify the difference of serum protein markers in the mother body of Down syndrome,and the serum peroxidase-1 protein and serum ceruloprotein are expected to be a marker for the maternal serum protein of Down's syndrome.